Page 19 - 《中国药房》2022年8期
P. 19
Guidelines for prevention of NSAID-related ulcer compli- sease[J]. Am J Gastroenterol,2013,108(3):308-328.
cations[J]. Am J Gastroenterol,2009,104(3):728-738. [69] FUCHS K H,BABIC B,BREITHAUPT W,et al. EAES
[59] FREEDBERG D E,KIM L S,YANG Y X. The risks and recommendations for the management of gastroesopha-
benefits of long-term use of proton pump inhibitors: geal reflux disease[J]. Surg Endosc,2014,28(6):1753-
expert review and best practice advice from the American 1773.
Gastroenterological Association[J]. Gastroenterology,2017, [70] IWAKIRI K,KINOSHITA Y,HABU Y,et al. Evi-
152(4):706-715. dence-based clinical practice guidelines for gastroesopha-
[60] HUNT R,LAZEBNIK L B,MARAKHOUSKI Y C,et al. geal reflux disease 2015[J]. J Gastroenterol,2016,51(8):
International consensus on guiding recommendations for 751-767.
management of patients with nonsteroidal antiinflamma- [71] WEERSINK R A,BOUMA M,BURGER D M,et al. Safe
tory drugs induced gastropathy-ICON-G[J]. Euroasian J use of proton pump inhibitors in patients with cirrhosis[J].
Hepatogastroenterol,2018,8(2):148-160. Br J Clin Pharmacol,2018,84(8):1806-1820.
[61] JOO M K,PARK C H,KIM J S,et al. Clinical guidelines [72] KAROL M D,MACHINIST J M,CAVANAUGH J M.
for drug-related peptic ulcer,2020 revised edition[J]. Gut Pharmacokinetics of lansoprazole in hemodialysis patients
Liver,2020,14(6):707-726. [J]. J Clin Pharmacol,1995,35(8):815-820.
[62] 中国医师协会急诊医师分会,中华医学会急诊医学分 [73] KDIGO Glomerular Diseases Work Group. KDIGO 2021
会,全军急救医学专业委员会,等.急性上消化道出血急 clinical practice guideline for the management of glome-
诊诊治流程专家共识:2020 版[J].中华急诊医学杂志, rular diseases[J]. Kidney Int,2021,100(4S):S1-S276.
2021,30(1):15-24. [74] 北京市科委重大项目《早期胃癌治疗规范研究》专家组,
[63] 中国药学会医院药学专业委员会,中华医学会临床药学 柴宁莉,翟亚奇,等.早期胃癌内镜下规范化切除的专家
分会,《质子泵抑制剂优化应用专家共识》写作组.质子 共识意见:2018,北京[J].中华胃肠内镜杂志,2019,36
泵抑制剂优化应用专家共识[J].中国医院药学杂志, (6):381-392.
2020,40(21):2195-2213. [75] OH T H,JUNG H Y,CHOI K D,et al. Degree of healing
[64] HUNT R,ARMSTRONG D,KATELARIS P,et al. World and healing-associated factors of endoscopic submucosal
Gastroenterology Organisation global guidelines:GERD dissection-induced ulcers after pantoprazole therapy for 4
global perspective on gastroesophageal reflux disease[J]. J weeks[J]. Dig Dis Sci,2009,54(7):1494-1499.
Clin Gastroenterol,2017,51(6):467-478. [76] NIIMI K,FUJISHIRO M,GOTO O,et al. Prospective sin-
[65] PAN T,WANG Y P,GUO Z,et al. Additional bedtime H2- gle-arm trial of two-week rabeprazole treatment for ulcer
receptor antagonist for the control of nocturnal gastric healing after gastric endoscopic submucosal dissection[J].
acid breakthrough[J]. Cochrane Database Syst Rev,2004 Dig Endosc,2012,24(2):110-116.
(4):CD004275. [77] TOMITA T,KIM Y,YAMASAKI T,et al. Prospective
[66] MAINIE I,TUTUIAN R,CASTELL D O. Addition of a randomized controlled trial to compare the effects of
H2 receptor antagonist to PPI improves acid control and omeprazole and famotidine in preventing delayed blee-
decreases nocturnal acid breakthrough[J]. J Clin Gastroen- ding and promoting ulcer healing after endoscopic submu-
terol,2008,42(6):676-679. cosal dissection[J]. J Gastroenterol Hepatol,2012,27(9):
[67] FACKLER W K,OURS T M,VAEZI M F,et al. Long- 1441-1446.
term effect of H2RA therapy on nocturnal gastric acid [78] 国家消化系统疾病临床医学研究中心,中华医学会消化
breakthrough[J]. Gastroenterology,2002,122(3):625-632. 内镜学分会,中国医师协会消化医师分会.胃内镜黏膜
[68] KATZ P O,GERSON L B,VELA M F. Guidelines for the 下剥离术围术期指南[J].中国医刊,2017,52(12):12-24.
diagnosis and management of gastroesophageal reflux di-
中国药房 2022年第33卷第8期 China Pharmacy 2022 Vol. 33 No. 8 ·909 ·